Earnings Call Insights: TOMI Environmental Solutions (TOMZ) Q1 2026 Management view "Q1 2026 marked a healthy start to the year" and "Revenue increased by 5% year-over-year and 67% sequentially from Q4 of 2025," CEO Halden Shane said, highlighting that "applicator sales in Q1 alone surpassed our total applicator sales for the entire year of 2025" and that the company generated "positive operating ...
Earnings Call Insights: TOMI Environmental Solutions (TOMZ) Q1 2026 Management view "Q1 2026 marked a healthy start to the year" and "Revenue increased by 5% year-over-year and 67% sequentially from Q4 of 2025," CEO Halden Shane said, highlighting that "applicator sales in Q1 alone surpassed our total applicator sales for the entire year of 2025" and that the company generated "positive operating cash flow of $296,000." (Chairman & CEO Halden Shane) Management tied the quarter’s commercial cadence to backlog and recurring services, saying, "At year-end of 2025, TOMI reported $1.6 million in backlog, which grew by $0.5 million by the close of Q1 2026 and is currently at $2.2 million," and added, "At the end of quarter 1, TOMI received 440,000 annual purchase orders for recurring decontamination services with a leading global medical technology company." (Chairman & CEO Shane) On international commercialization, management said, "In February, we received official authorization from the U.K. Health and Safety Executive," "In March, we secured product authorization from the Dutch regulatory authority," and "this past week, we received notification of further approvals in Germany, Belgium, Denmark and Hungary." (Chairman & CEO Shane) The company announced a strategic transaction, stating, "On April 30, 2026, we executed a nonbinding letter of intent to merge with Carbonium Core, Inc.," and under the LOI, "Former stockholders would receive TOMI common stock equal to 19.99% of shares outstanding prior to the merger, along with shares of a newly created series of convertible preferred stock, implying an enterprise valuation of $120 million." (Chairman & CEO Shane) CFO David Vanston framed Q1 results and one-time comparability, saying, "Revenue for Q1 '26 was $1.6 million," "The net loss was $811,000 or $0.04 a share," and "Q1 '25 net loss included a nonrecurring employee retention credit of $535,000 and related interest of $83,000." (Chief Financial Officer David Vanston) C...
Earnings Call Insights: Vaxart (VXRT) Q1 2026 Management View “In the first quarter, we made meaningful progress advancing our clinical programs and preparing for key data milestones that we believe will help demonstrate the value of our oral vaccine platform.” (President, CEO & Director Steven Lo) “Specifically, our work during the first quarter was focused on the steps needed to disclose data fr...
Earnings Call Insights: Vaxart (VXRT) Q1 2026 Management View “In the first quarter, we made meaningful progress advancing our clinical programs and preparing for key data milestones that we believe will help demonstrate the value of our oral vaccine platform.” (President, CEO & Director Steven Lo) “Specifically, our work during the first quarter was focused on the steps needed to disclose data from the 400-person sentinel cohort of our Phase IIb COVID-19 trial.” (President, CEO & Director Lo) “To further strengthen our Board and add clinical and strategic oversight, we were pleased to welcome Dr. James Breitmeyer to our Board of Directors in April.” (President, CEO & Director Lo) “On the operational side, we completed our headquarters move in April, consolidating and reducing our footprint and also established a $25 million share purchase agreement with Lincoln Park Capital. No shares have been sold to date, and the use of this purchase agreement is subject to the company's discretion.” (President, CEO & Director Lo) “Vaxart management is currently blinded to the results and has not reviewed the data.” (Chief Medical Officer James Cummings) “More definitive insights are expected to come from our main cohort of approximately 5,000 participants, which is designed and powered to evaluate relative efficacy and safety.” (Chief Medical Officer Cummings) “We are prepared to initiate our next clinical trial in 2026, depending on a partnership or the receipt of other funding.” (Senior VP & Chief Scientific Officer Sean Tucker) “Vaxart ended the first quarter with cash, cash equivalents and short-term investments of $61 million.” (CFO, Principal Accounting Officer & Principal Financial Officer Jeroen Grasman) Outlook “While we are still aiming to release the top line results in Q2, it's important to remember that we are working with the contractual partner, and we're not in full control of that timing.” (Chief Medical Officer Cummings) “We anticipate the primary efficacy and...
Devrimb/iStock via Getty Images By Elior Manier Metals have been trading in confusion since the beginning of the war, with particular inflation and price action dynamics adding to the doubts. In recent trading, the oil-to-gold inverted relationship has somewhat abated, and this forms the path to newer narratives for the precious commodities market. Gold vs WTI Crude Inverse Correlation – Source: T...
Devrimb/iStock via Getty Images By Elior Manier Metals have been trading in confusion since the beginning of the war, with particular inflation and price action dynamics adding to the doubts. In recent trading, the oil-to-gold inverted relationship has somewhat abated, and this forms the path to newer narratives for the precious commodities market. Gold vs WTI Crude Inverse Correlation – Source: TradingView. May 8, 2026 While the price action has remained mostly sideways, a few metals have begun to reject their selling attempts, providing proof that the general bear trend is exhausting. The best example is seen in copper, breaking its war highs throughout this week, but also silver, bouncing back close to 10% off of its 2026 year-beginning prices. Weekly momentum is showing some strong signs, as can be seen with the gold weekly chart. The RSI has completely stopped its downward trajectory, supported by the huge weekly hammer, and is now looking to confirm its rise. It wouldn't be surprising to see strong action in the asset class in coming weeks. Gold (XAU/USD) Weekly Chart, May 8, 2026 – Source: TradingView Let's explore the recent shifts in an intraday timeframe analysis of gold (XAU/USD) and silver (XAG/USD) to identify where the key levels to watch for breakouts. Gold (XAU/USD) 4H Chart and levels Gold (XAU/USD) 4H Chart, May 8, 2026 – Source: TradingView Gold has officially broken out of its descending channel formed since April 17. While the picture is still quite rangy ($4,500 to $4,900), the recent breakout attempt pulled back to the 4H 200-period MA ($4,663) before bouncing higher, helping for chances of a break-retest pattern at the mid-range pivot. To confirm on the intraday, look for a break above $4,760; the action gets especially more bullish above $4,900. Intraday timeframe levels to watch for gold (XAU/USD): Resistance Levels: $4,850 to $4,900 major resistance (bullish above) $5,100 pivotal resistance $5,400 mini resistance Support Levels: 4H 200-per...
What The Indiana Primaries Tell Us About Trump's Grip On The GOP Tuesday night’s primaries in Indiana were not subtle . Five of seven Republican state senators who had blocked a congressional redistricting map favored by President Donald Trump lost their primary races to Trump-backed challengers. The message, delivered cleanly through the ballot box, couldn’t have been clearer. Twenty-one Republic...
What The Indiana Primaries Tell Us About Trump's Grip On The GOP Tuesday night’s primaries in Indiana were not subtle . Five of seven Republican state senators who had blocked a congressional redistricting map favored by President Donald Trump lost their primary races to Trump-backed challengers. The message, delivered cleanly through the ballot box, couldn’t have been clearer. Twenty-one Republicans in the Indiana Senate voted against a new congressional map that would likely have added two GOP-leaning U.S. House districts. Eight of those dissenters were up for reelection this cycle, and seven drew primary challengers who carried Trump's explicit endorsement. By Tuesday night, the Associated Press had projected wins for at least five of those challengers. Only state Sen. Greg Goode managed to hold his seat among the targeted incumbents. The rest are heading for the exits. Trump's play here was neither complicated nor ambiguous. He targeted members of his own party, not for ideological apostasy or opposition to his signature policies, but for refusing to help the GOP fight back against decades of Democrat gerrymanders. It was a demonstration of leverage and political capital, and it worked. The incumbents who lost weren't rogue progressives or even moderate Republicans, either. They were conventional Republicans who had largely supported Trump on major national issues, and didn’t expect to become Trump targets. That calculation turned out to be wrong, and the lesson other incumbents will draw is obvious: the scope of what constitutes a disqualifying defection is wider than many assumed. And there are likely to be other victims of Trump’s wrath. In Kentucky's 4th Congressional District, Trump has endorsed Ed Gallrein against Rep. Thomas Massie, a Republican who has broken with the president on the Iran war, tariffs, and quit a few other things. In Louisiana, Trump is backing Rep. Julia Letlow against incumbent Sen. Bill Cassidy, a physician who has pushed back agains...
With a YTD Return of 15.76% as of May 7, QUALCOMM Incorporated (NASDAQ:QCOM) is included among the 10 Best Stocks to Buy to Beat the S&P 500. On May 1, Argus raised its price recommendation on QUALCOMM Incorporated (NASDAQ:QCOM) to $220 from $180. It reiterated a Buy rating following the company’s earnings report. The firm said Qualcomm […]
With a YTD Return of 15.76% as of May 7, QUALCOMM Incorporated (NASDAQ:QCOM) is included among the 10 Best Stocks to Buy to Beat the S&P 500. On May 1, Argus raised its price recommendation on QUALCOMM Incorporated (NASDAQ:QCOM) to $220 from $180. It reiterated a Buy rating following the company’s earnings report. The firm said Qualcomm […]